

**REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
FOR
THE DAVID HIDE ASTHMA AND ALLERGY
RESEARCH CENTRE**

Bright Brown Limited
Chartered Accountants
Exchange House
St. Cross Lane
Newport
Isle of Wight
PO30 5BZ

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

	Page
Report of the Trustees	1 to 3
Independent Examiner's Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7 to 13
Detailed Statement of Financial Activities	14 to 15

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 MARCH 2023**

The trustees present their report with the financial statements of the charity for the year ended 31 March 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objects of the charity

The charity provides the opportunity to further the knowledge of diagnosis and management of allergic diseases based on research. It secures the research and education platform from which much has been achieved in the last two decades.

The charity operates from a purpose-built centre within St. Mary's Hospital and its main functions are:

- to provide a facility for diagnosis and management of allergy-related disorders within the NHS;
- to increase the understanding of the causes and treatment of allergic diseases by means of an evolving programme of research; and
- to offer training in clinical allergy to doctors, medical students and other health professionals.

In shaping our objectives for the year and planning our activities, the trustees have considered the Charity Commission's guidance on public benefit.

ACHIEVEMENT AND PERFORMANCE

Review of the development and achievement of the charity

In 2022 research activity continued at the David Hide Asthma & Allergy Centre. The Research team has been reduced over the year to reflect activity but continue to deliver to target.

Study activity:

Patterns of adult food allergy in the UK population (PAFA Stage 3). - funded by the Food Standards Agency (FSA) and sponsored by Manchester University NHS Foundation Trust. The David Hide Centre carried out recruitment of individuals from the Isle of Wight Birth Cohort who had probable food allergies.

The Research team had the opportunity to set up a commercial CRN Wessex led Immunisation study. The Harmonie Study is looking at a new medicine which protects against respiratory syncytial virus (RSV). The Study is looking at how strongly babies can be protected from serious illness due to RSV infection by comparing a single dose of antibody with no intervention.

The Preschool wheeze study (Breathing Together) was completed, ending the study by following up the children at 4-5 years of age.

EOSA - Epigenetics of Severe Asthma Study re-started early in 2023, recruiting adults with mild asthma and healthy volunteers (no asthma). Further funding from the NIH (USA) was secured through the University of California, San Diego.

FINANCIAL REVIEW

Reserves policy

It is the policy of the charity to maintain unrestricted funds, which are the free reserves of the charity, at a level which equates to at least twelve months unrestricted expenditure. At this level the reserves provide sufficient funds to continue the activities of the charity, should there be a significant drop in funding, while new research projects are put in place. In practice, the charity holds additional reserves to support over 10 years of expenditure at the current level - held to support the future funding of the charities objectives and to maintain expenditure in advance of grant funding being received.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 MARCH 2023**

FINANCIAL REVIEW

Results for the financial year

Total income for the year amounted to £115,716 (2022: £66,074). Costs relating to charitable activities amounted to £29,669 (2022: £25,735). Unrestricted funds and restricted funds carried forward at the end of the year amounted to £385,026 (2022: £298,979).

FUTURE PLANS

Planning for future studies continues:

IW Birth Cohort 34 Year Follow-Up will start later in 2023.

PREVENT Primary Prevention of Asthma using House Dust Mite Immunotherapy. The proposal will be submitted to the NIH in September 2023.

Applications to the MRC and NIH- related to House Dust Mite Allergy

Food allergy prevention trial - PGfAR - stage 2 application is due to be submitted August 2023.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Organisation

The trustees who served during the year are set out below. The trustees meet regularly and meetings are presided over by a Chairman who is appointed annually.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1020201

Principal address

The David Hide Asthma and Allergy
Research Centre
St Mary's Hospital
Newport
Isle of Wight
PO30 5TG

Trustees

Dr C J A Andrews
Dr Y H Hide
Mrs E M Bell
Mrs J A Griffin
Dr M R Stainer
Mrs S Matthews
Mrs C Stone

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE DAVID HIDE ASTHMA AND ALLERGY
RESEARCH CENTRE**

Independent examiner's report to the trustees of The David Hide Asthma and Allergy Research Centre

I report to the charity trustees on my examination of the accounts of The David Hide Asthma and Allergy Research Centre (the Trust) for the year ended 31 March 2023.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').


I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



D J P Stevens A C A

Bright Brown Limited
Chartered Accountants
St. Cross Lane
Newport
PO30 5BZ

Date: 26/10/23

**THE DAVID HIDE ASTHMA AND ALLERGY
RESEARCH CENTRE**


**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 MARCH 2023**

REFERENCE AND ADMINISTRATIVE DETAILS

Independent Examiner

D J P Stevens A C A
Bright Brown Limited
Chartered Accountants
Exchange House
St. Cross Lane
Newport
Isle of Wight
PO30 5BZ

Approved by order of the board of trustees on 20/10/23 and signed on its behalf by:




Dr C J A Andrews - Trustee

**THE DAVID HIDE ASTHMA AND ALLERGY
RESEARCH CENTRE**

**BALANCE SHEET
31 MARCH 2023**

	Notes	2023 Unrestricted funds £	2022 Total funds £
FIXED ASSETS			
Tangible assets	6	18,452	21,266
CURRENT ASSETS			
Debtors	7	519	126
Cash at bank		367,515	278,855
		<u>368,034</u>	<u>278,981</u>
CREDITORS			
Amounts falling due within one year	8	(1,460)	(1,268)
		<u>366,574</u>	<u>277,713</u>
NET CURRENT ASSETS			
		<u>385,026</u>	<u>298,979</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>385,026</u>	<u>298,979</u>
NET ASSETS			
		<u>385,026</u>	<u>298,979</u>
FUNDS	9		
Unrestricted funds		385,026	298,979
TOTAL FUNDS		<u>385,026</u>	<u>298,979</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 28/10/23 and were signed on its behalf by:


 Dr C. J. A. Andrews - Trustee

The notes form part of these financial statements

**THE DAVID HIDE ASTHMA AND ALLERGY
RESEARCH CENTRE**

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2023**

		2023 Unrestricted funds £	2022 Total funds £
INCOME AND ENDOWMENTS FROM	Notes		
Donations and legacies		2,827	4,933
Charitable activities			
Research, diagnosis and management of allergic diseases		112,085	60,969
Investment income	2	779	172
Other income		25	-
Total		<u>115,716</u>	<u>66,074</u>
EXPENDITURE ON			
Charitable activities			
Research, diagnosis and management of allergic diseases		<u>29,669</u>	<u>25,735</u>
NET INCOME		86,047	40,339
RECONCILIATION OF FUNDS			
Total funds brought forward		298,979	258,640
TOTAL FUNDS CARRIED FORWARD		<u><u>385,026</u></u>	<u><u>298,979</u></u>

The notes form part of these financial statements

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

- Building - Over fifty years
- Equipment - Straight line over 3 to 7 years

Fund accounting

a) General Fund

The charity's general funds consist of funds which the charity may use for its purposes at its discretion.

b) Restricted Funds

Income received into the restricted fund represents the receipt of funds for specific purposes. Expenditure charged against the restricted funds represents revenue costs incurred during the year for the purpose specified by the fund.

c) Designated Funds

Designated funds are funds established by the committee from time to time for specific projects or purposes, are not in any way restricted and any surplus or deficit will be transferred to/from the general purpose fund when the designated fund is closed.

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2023

2. INVESTMENT INCOME

	2023	2022
	£	£
UK Bank interest	779	172
	<u>779</u>	<u>172</u>

3. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2023 nor for the year ended 31 March 2022.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 March 2023 nor for the year ended 31 March 2022.

4. STAFF COSTS

The average monthly number of employees during the year was as follows:

	2023	2022
	4	6
Research, diagnosis and management	<u>4</u>	<u>6</u>

No employees received emoluments in excess of £60,000.

All employee costs shown above are contributions to NHS Trust wages that have been recharged to the charity.

5. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £
INCOME AND ENDOWMENTS FROM	
Donations and legacies	4,933
Charitable activities	
Research, diagnosis and management of allergic diseases	60,969
Investment income	172
Total	<u>66,074</u>
EXPENDITURE ON	
Charitable activities	
Research, diagnosis and management of allergic diseases	25,735
NET INCOME	<u>40,339</u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2023

5. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted funds £
RECONCILIATION OF FUNDS	
Total funds brought forward	258,640
TOTAL FUNDS CARRIED FORWARD	<u>298,979</u>

6. TANGIBLE FIXED ASSETS

	Building £	Equipment £	Totals £
COST			
At 1 April 2022	30,000	41,185	71,185
Disposals	-	(12,996)	(12,996)
At 31 March 2023	<u>30,000</u>	<u>28,189</u>	<u>58,189</u>
DEPRECIATION			
At 1 April 2022	15,000	34,919	49,919
Charge for year	600	2,215	2,815
Eliminated on disposal	-	(12,997)	(12,997)
At 31 March 2023	<u>15,600</u>	<u>24,137</u>	<u>39,737</u>
NET BOOK VALUE			
At 31 March 2023	<u>14,400</u>	<u>4,052</u>	<u>18,452</u>
At 31 March 2022	<u>15,000</u>	<u>6,266</u>	<u>21,266</u>

All of the fixed assets are used in the direct furtherance of the charity's objectives.

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Other debtors	<u>519</u>	<u>126</u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2023

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Sundry creditors and accrued expenses	<u>1,460</u>	<u>1,268</u>

9. MOVEMENT IN FUNDS

	At 1.4.22	Net movement in funds	At 31.3.23
	£	£	£
Unrestricted funds			
Research, diagnosis and management of allergic diseases	258,009	89,182	347,191
PI Fund (H Ramesh)	9,121	(936)	8,185
PI Fund (R Kurukulaaratchy)	18,829	(4,017)	14,812
PI Fund (G Roberts)	13,020	1,818	14,838
	<u>298,979</u>	<u>86,047</u>	<u>385,026</u>
TOTAL FUNDS	<u>298,979</u>	<u>86,047</u>	<u>385,026</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
Research, diagnosis and management of allergic diseases	101,732	(12,550)	89,182
PI Fund (H Ramesh)	-	(936)	(936)
PI Fund (R Kurukulaaratchy)	1,652	(5,669)	(4,017)
PI Fund (G Roberts)	12,332	(10,514)	1,818
	<u>115,716</u>	<u>(29,669)</u>	<u>86,047</u>
TOTAL FUNDS	<u>115,716</u>	<u>(29,669)</u>	<u>86,047</u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2023

9. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.4.21 £	Net movement in funds £	At 31.3.22 £
Unrestricted funds			
Research, diagnosis and management of allergic diseases	233,639	24,370	258,009
PI Fund (H Ramesh)	9,121	-	9,121
PI Fund (R Kurukulaaratchy)	13,480	5,349	18,829
PI Fund (G Roberts)	2,400	10,620	13,020
	<u>258,640</u>	<u>40,339</u>	<u>298,979</u>
TOTAL FUNDS	<u>258,640</u>	<u>40,339</u>	<u>298,979</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
Research, diagnosis and management of allergic diseases	50,105	(25,735)	24,370
PI Fund (R Kurukulaaratchy)	5,349	-	5,349
PI Fund (G Roberts)	10,620	-	10,620
	<u>66,074</u>	<u>(25,735)</u>	<u>40,339</u>
TOTAL FUNDS	<u>66,074</u>	<u>(25,735)</u>	<u>40,339</u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2023

9. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.4.21 £	Net movement in funds £	At 31.3.23 £
Unrestricted funds			
Research, diagnosis and management of allergic diseases	233,639	113,552	347,191
PI Fund (H Ramesh)	9,121	(936)	8,185
PI Fund (R Kurukulaaratchy)	13,480	1,332	14,812
PI Fund (G Roberts)	2,400	12,438	14,838
	<u>258,640</u>	<u>126,386</u>	<u>385,026</u>
TOTAL FUNDS	<u>258,640</u>	<u>126,386</u>	<u>385,026</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
Research, diagnosis and management of allergic diseases	151,837	(38,285)	113,552
PI Fund (H Ramesh)	-	(936)	(936)
PI Fund (R Kurukulaaratchy)	7,001	(5,669)	1,332
PI Fund (G Roberts)	22,952	(10,514)	12,438
	<u>181,790</u>	<u>(55,404)</u>	<u>126,386</u>
TOTAL FUNDS	<u>181,790</u>	<u>(55,404)</u>	<u>126,386</u>

The research, diagnosis and management of allergic diseases fund is made up of funds, less related expenditure, for the continuance of the educational work undertaken by the centre. Expenses may include subscriptions to asthma and allergy related organisations, attending meetings, courses and conferences including registration, travel expenses and accommodation. It will also fund the purchase of relevant journals and books for the Centre library.

The PI Funds are designated funds made up of funds, less related expenditure, for research by Dr Hasan and Dr Ramesh. Expenses will be allocated at the discretion of the doctors.

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2023

10. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 March 2023.

11. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Tangible fixed assets £	Net current assets £	Total £
Restricted funds:	-	-	-
Unrestricted funds:	29,805	257,960	287,765
	29,805	257,960	287,765

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2023

	2023 Total funds £	2022 Total funds £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	300	300
Pollen funding	2,527	4,633
	<u>2,827</u>	<u>4,933</u>
Investment income		
UK Bank interest	779	172
Charitable activities		
Grants	98,101	45,000
PI Fund	13,984	15,969
	<u>112,085</u>	<u>60,969</u>
Other income		
Other income	25	-
Total incoming resources	<u>115,716</u>	<u>66,074</u>
EXPENDITURE		
Charitable activities		
Telephone and internet	436	301
Postage and stationery	125	415
Miscellaneous	1,456	2,593
Travel	536	102
Gifts, vouchers and refreshments	500	-
Medical supplies and repairs	4,898	7,342
Financial services	1,890	1,932
Course and conference costs	400	-
Subscriptions	185	-
I.T costs	4,924	-
Contribution to Dyson	-	1,500
Breathing together charge	-	5,931
Studentship support	10,329	-
Depreciation of tangible fixed assets	2,814	2,814
Loss on sale of tangible fixed assets	-	1,701
	<u>28,493</u>	<u>24,631</u>

This page does not form part of the statutory financial statements

**THE DAVID HIDE ASTHMA AND ALLERGY
RESEARCH CENTRE**

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2023**

	2023 Total funds £	2022 Total funds £
Support costs		
Governance costs		
Independent examiners fees	1,176	1,104
Total resources expended	29,669	25,735
Net income	86,047	40,339

This page does not form part of the statutory financial statements

